Special Issue

Therapeutic Antibody Development: What Are We Learning along the Way?

Message from the Guest Editors

There is now ample evidence that monoclonal antibodies are very powerful drugs. As the properties needed for an antibody to be a good drug differ from those of natural and even pathogenic antibodies, many new scientific questions have arisen from pharmacological and pharmaceutical questions.

The IgG1 subclass has been largely privileged, but many other natural or engineered heavy-chain isotypes are now available to adapt molecules to the pharmacological or pharmaceutical needs of long half-lives, reduced immunogenicity, reduced or sometimes increased immune activation, etc. A great effort of creativity has led to bi- or multispecific antibodies with totally new properties, bringing antigens, receptors and cells together. Observing and investigating the side effects of antibodies on very large cohorts has revealed off-target side effects, leading to the conclusion that antibodies are not as specific as we thought, reviving the questions of polyreactivity and polyspecificity.

Papers related to any molecular aspects of antibodies, including bioinformatics studies, will be considered for this Special Issue.

Guest Editors

Dr. Anne Poupon

PRC, INRAe, CNRS, Université de Tours, INRIA, 37380 Nouzilly, France

Prof. Dr. Hervé Watier

EA 7501 GICC, Université de Tours, 37032 Tours, France

Deadline for manuscript submissions

closed (15 November 2022)



International Journal of Molecular Sciences

an Open Access Journal by MDPI

Impact Factor 4.9 CiteScore 9.0 Indexed in PubMed



mdpi.com/si/105979

International Journal of Molecular Sciences Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 ijms@mdpi.com

mdpi.com/journal/ ijms





International Journal of Molecular Sciences

an Open Access Journal by MDPI

Impact Factor 4.9 CiteScore 9.0 Indexed in PubMed





Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Editor-in-Chief

Prof. Dr. Maurizio Battino

Department of Odontostomatologic and Specialized Clinical Sciences, Sez-Biochimica, Faculty of Medicine, Università Politecnica delle Marche, Via Ranieri 65, 60100 Ancona, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

